Ginkgo Bioworks Holdings Chief Financial Officer Steven Coen sold 330 shares of Class A common stock on August 24, 2026, for $2,302 at $6.977 per share. The transaction was executed as a sell-to-cover to satisfy tax withholding obligations arising from the vesting of restricted stock units, according to regulatory filings.
The restricted stock units vested on August 21, 2026, following two separate vesting schedules initiated on May 1, 2024. A total of 743 shares were acquired through these vesting events, with 587 shares subject to a 25% initial vesting followed by 36 equal monthly installments, and 156 shares subject to a 2/48ths initial vesting followed by 46 equal monthly installments. Coen retained 51,851 shares of Ginkgo Bioworks common stock after the transaction.
Ginkgo Bioworks reported a Q2 2026 adjusted loss of $0.92 per share, an improvement from the anticipated $1.05 loss, but revenue declined 48% year-over-year to $20 million, missing the $29.9 million forecast. The company ended the quarter with $389 million in total liquidity and maintained its full-year cash burn guidance of $125 million to $150 million.
Analysts at TD Cowen downgraded Ginkgo Bioworks from Buy to Hold and reduced the price target from $12.00 to $9.00, citing growth uncertainty and the capital-intensive transition toward Datapoints and Autonomous Labs. The stock, which closed at $7.54, remains significantly below its 52-week high of $17.58 and is noted by InvestingPro as burning cash rapidly.
